Oxford BioTherapeutics (OBT) has added two new names to a board now boasting significant experience in developing immuno-oncology and antibody-based therapies. 9 February 2017
US biotech firm Juno Therapeutics has appointed Corsee Sanders as executive vice president and head of development operations, effective immediately. 29 January 2017
Monoclonal antibody specialist Kymab has appointed Arndt Schottelius as its first executive vice president of research and development (R&D). 23 January 2017
Friday saw the launch of a new US biotech company, Vir Biotechnology, which is focussed developing cures, treatments and preventions for challenging infectious diseases, with former Biogen chief executive George Scangos heading a team of scientific and industry leaders. 9 January 2017
3SBio announced today that Zhenping Zhu will join the Chinese biotech firm as president of research & development and chief scientific officer. 9 January 2017
David-Alexandre “DA” Gros has joined Neurocrine Biosciences as president and chief operating officer, the American biotech group announced today. 6 January 2017
Biotech firm Sobi have announced the recruitment of Armin Reininger as senior vice president and head of global medical and scientific affairs. 5 January 2017
US-based biotech firm Gilead has recruited Alessandro Riva as senior vice president of hematology and oncology. Dr Riva helped develop more than 20 cancer compounds as head of oncology at Swiss giant Novartis, including both targeted and immune-oncology treatments. 4 January 2017
Ireland-headquartered Shire has announced the appointment of Ian Clark as a non-executive director of the company with effect from today (January 3). 3 January 2017
US biotech major Biogen has now selected a new chief executive to replace outgoing incumbent George Scangos, who has led the company since 2010 but announced his intention to leave last year, from its own ranks. 20 December 2016
Genentech, the US-based biotech unit of Swiss pharma giant Roche, has announced its new chief executive after the retirement of Ian Clark. 16 December 2016
Shares of US biotech firm Alexion Pharmaceuticals plunged as much as 15.6% to $111.44 on Monday, after it was revealed that its chief executive David Hallal had resigned for personal reasons, and chief financial officer Vikas Sinha was leaving to pursue other opportunities. 13 December 2016
Last week, US biotech major Gilead Sciences terminated its licensing deal with GlobeImmune to develop a hepatitis-B (HBV) drug, GS-4774, and returned rights to the drug. 22 November 2016
US biotech major Biogen has named two members to the executive management team of Bioverativ, its planned spin-off company focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. 16 November 2016
French biotech firm Erytech Pharma today announced the appointments of Dr Alexander Scheer, as the company’s chief scientific officer and Jean-Sébastien Cleiftie, as chief business officer. 27 October 2016
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024